NCT00348062已完成4 期
A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
Evaluate the incidence of hyperemia in patients using bimatoprost and to determine if simple interventions reduce its incidence and to assess the value of detailed instruction in increasing patient compliance and willingness to continue bimatoprost therapy, despite the occurrence of hyperemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •· Male or female > 18 years of age
- •No prior use of bimatoprost
- •Diagnosis of open-angle glaucoma or ocular hypertension
- •Ability to provide informed consent and likely to complete all study visits
排除标准
- •· Known contraindication to bimatoprost
- •Uncontrolled systemic disease
- •Active ocular disease other than glaucoma or ocular hypertension
- •Required use of ocular medications other than the study medications during the study (intermittent use of artificial tear solutions will be permitted)
- •History of intraocular surgery within the last 3 months
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)Ocular HypertensionGlaucoma, Open-AngleNCT01594970Allergan800
已完成
4 期
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to LatanoprostGlaucomaNCT00347841Innovative Medical
已完成
不适用
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular HypertensionGlaucoma, Open-AngleOcular HypertensionNCT01646151Allergan2,580
已完成
1 期
A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular HypertensionOcular HypertensionOpen-Angle GlaucomaNCT02742649ForSight Vision5, Inc.55
已完成
2 期
Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic AlopeciaBaldnessAlopecia, AndrogeneticAlopeciaNCT01325337Allergan307